HONG KONG – South Korean authorities are expected to ease restrictions for the country's biotech industry, especially for regulations surrounding gene therapies and organ donation.
HONG KONG – South Korean authorities are expected to ease restrictions for the country’s biotech industry, especially for regulations surrounding gene therapies and organ donation.
HONG KONG – KBP Biosciences Co. Ltd. closed a $76 million series A financing to, among other things, advance its lead asset, KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease entering phase IIb studies. The cash will also support moving its headquarters to the U.S.
HONG KONG – CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, has made plans to acquire a 39.56 percent stake in Wuhan YZY Biopharma Co. Ltd. in a deal worth up to ¥356 million (US$54.6 million).
HONG KONG – Singapore isn't just becoming a biotech hub. The island nation's biotech ecosystem is at "an inflection point," said Benjamin Seet, executive director of the biomedical research council at A*STAR (The Agency for Science, Technology and Research), a statutory board under the Ministry of Trade and Industry.
HONG KONG – CSPC Pharmaceutical Group Ltd., of Shijiazhuang, China, has made plans to acquire a 39.56 percent stake in Wuhan YZY Biopharma Co. Ltd. in a deal worth up to ¥356 million (US$54.6 million).
HONG KONG – KBP Biosciences Co. Ltd. closed a $76 million series A financing to, among other things, advance its lead asset, KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease entering phase IIb studies. The cash will also support moving its headquarters to the U.S.
